Bio Medica Laboratories IPO
Pharmaceuticals • ₹52.43 Cr
Medium risk because:
- 5 material risk factors disclosed in DRHP
- High customer concentration flagged in the DRHP
- Regulatory or legal risks cited in DRHP
IPOFins risk score from DRHP risk factors, subscription demand & issue structure
Price Band
₹139
Lot Size
1000 shares
Issue Size
₹52.43 Cr
Open
21 May 2026
Close
25 May 2026
Subscription
2.19×
IPO Schedule
| Issue Open Date | 21 May 2026 |
| Issue Close Date | 25 May 2026 |
| Listing Date | 28 May 2026 |
About Bio Medica Laboratories
Bio Medica Laboratories Limited (BMLL) is a Madhya Pradesh-based company engaged in the manufacturing of pharmaceutical parenteral formulations. The company was incorporated in 2015 and converted into a public limited company in October 2024. BMLL manufactures generic drugs in the form of injectables, specifically liquid injections and dry powder injections, available in single-dose and multi-dose forms. These products cater to both human and veterinary needs. The company operates on a B2B contract manufacturing model, producing formulations for other companies as per their specific requirements, and does not sell directly to end users. The company operates from a single manufacturing facility in Madhya Pradesh. It holds Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) certificates issued by the Food and Drugs Administration, Madhya Pradesh. Its in-house laboratory is equipped with instruments including HPLC, GC, and UV-Vis Spectrophotometer for testing and quality control purposes.
Company Details
Founders / Promoters
Mr. Pradeep Mehta
Founded
2015
Registrar
SKYLINE
Documents
DRHP / RHP Document (PDF)
View official prospectus →
Investment Analysis
Bio Medica Laboratories — IPOFins Verdict
QuantitativeDriven by QIB demand at 15.9x and moderate disclosed risk (5/10), Bio Medica Laboratories listed at a discount of 20.0% to its issue price. SME listings are also thinner and more volatile after listing. The picture is mixed — treat this as one input alongside the DRHP, valuation, and your own risk appetite.
- The company is led by promoters Mr. Pradeep Mehta and Mr. Mukesh Mehta, who collectively have over 37 years of experience in the pharmaceutical industry. This leadership has been instrumental in guidi
- BMLL manufactures 71 types of formulations, spanning generic drugs, branded pharmaceuticals, and over-the-counter (OTC) products. These are produced in both single-dose and multi-dose forms, catering
- The company holds GMP and GLP certificates issued by the Food and Drug Administration, Madhya Pradesh. It claims to maintain an in-house quality control team that conducts testing of both raw material
- The company claims to operate an in-house laboratory equipped with instruments, including HPLC, gas chromatography, UV-Vis spectrophotometer, and a polarimeter, among others. These are used for physic
- The company's employee attrition rate reduced from 14.12% in FY23 and has continued to decline through FY24 and FY25. This indicates a degree of workforce stability, which is operationally relevant fo
Score breakdown — what drove this verdict
Moderate risk from DRHP → score +0.0
Institutional subscription → score +2.0
Actual listing outcome → score −1.5
SME IPOs have lower liquidity after listing → score −0.5
Base score: 5.0 · Final score = base + all factor adjustments, capped 1–10. Full methodology →
IPOFins Score is a quantitative signal from subscription demand, disclosed risk, and listing data — not investment advice. Not SEBI-registered.
Listing Performance
Issue Price
₹139
Listing Price
₹111.2
Listing Gain/Loss
-20.00%
Listing Date
28 May 2026
Price Since Listing
Returns are measured against the ₹139 issue price.
Listing
₹111.2
-20.0%
Current
₹158.95
+14.4%
Want to buy this stock?
Trade Bio Medica Laboratories on the secondary market
FAQ
What is the price band of Bio Medica Laboratories IPO?
The price band is ₹139 per share with a lot size of 1000 shares. Minimum investment: ₹1,39,000.
What does Bio Medica Laboratories do?
Bio Medica Laboratories Limited (BMLL) is a Madhya Pradesh-based company engaged in the manufacturing of pharmaceutical parenteral formulations. The company was incorporated in 2015 and converted into a public limited company in October 2024. BMLL manufactures generic drugs in the form of injectables, specifically liquid injections and dry powder injections, available in single-dose and multi-dose forms. These products cater to both human and veterinary needs. The company operates on a B2B contract manufacturing model, producing formulations for other companies as per their specific requirements, and does not sell directly to end users. The company operates from a single manufacturing facility in Madhya Pradesh. It holds Good Manufacturing Practices (GMP) and Good Laboratory Practices (GLP) certificates issued by the Food and Drugs Administration, Madhya Pradesh. Its in-house laboratory is equipped with instruments including HPLC, GC, and UV-Vis Spectrophotometer for testing and quality control purposes.
Should I apply for Bio Medica Laboratories IPO?
Bio Medica Laboratories listed at ₹111.2 (-20.0% discount to the ₹139 issue price) after 2.2x subscription. IPOFins Score 5/10: Driven by QIB demand at 15.9x and moderate disclosed risk (5/10), Bio Medica Laboratories listed at a discount of 20.0% to its issue price. SME listings are also thinner and more volatile after listing. The picture is mixed — treat this as one input alongside the DRHP, valuation, and your own risk appetite.
Who founded Bio Medica Laboratories?
Bio Medica Laboratories was founded by Mr. Pradeep Mehta in 2015.